Skip to main content


Continuing Education (CME)

2023 SNO/ASCO CNS Cancer Conference
August 10-12, 2023 

This activity is provided by the Society for Neuro-Oncology.
This activity is supported by an educational grant from Seagen.

Target Audience
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, and Patient Advocates.

Statement of Need/Program Overview
The 2023 SNO/ASCO CNS Cancer Conference — Accelerating therapeutic discovery and advancing care of patients with primary and metastatic CNS malignancies — will be held on August 10-12, 2023, in San Francisco, California. The goal of this annual Conference is to provide a deeper dive into the basic science of brain metastases and neuro-oncology clinical trials. Together we will make significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system.

This collaborative Conference will:
  • stimulate basic, translational, and clinical research in CNS metastases;
  • engage clinical researchers in innovative trial designs for primary and secondary CNS malignancies;
  • address the needs of patients with intracranial tumors.
These areas of great unmet need will be addressed in a dynamic and interactive framework. The structure brings together various disciplines to emphasize basic and translational research on brain metastases as well as clinical trial design and outcomes in primary and metastatic intracranial tumors. Research highlighting novel approaches, innovative ideas, and recent advances in neuro-oncology clinical trials will be presented and discussed. There will be a unique opportunity for collaboration and exchange of ideas between those dedicated to the science and care of patients with primary and secondary malignancies of the CNS. 

Educational Objectives
After participating in this CME activity, participants should be able to:  
  • Explain new CNS-penetrant systemic agents in the context of multidisciplinary care for the treatment of CNS metastases
  • Discuss new developments in local therapeutic approaches and diagnostics in the treatment of CNS metastases.
  • Explain the role of the tumor microenvironment in CNS metastases.
  • Compare clinical trials designs incorporating recent advances such as liquid biopsy, novel prognostic biomarkers, and advanced neuroimaging for the treatment of CNS malignancies.
  • Outline challenges for the development and approval of novel therapies for CNS cancers.

Program Agenda
Click here to view the current program.

Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation
The Society for Neuro-Oncology designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit
In order to receive credit for this activity, the participant must attend the meeting in-person and complete the program evaluation. An individualized CME/CE evaluation link will be emailed to each participant within one week of the conference conclusion from The Society for Neuro-Oncology with the subject line "Claim CME for 2023 SNO-ASCO Conference." 

Deadline to claim CE Credit will be Monday November 13, 2023.

To claim credit, click here.  
*The access code can be found in the post conference email. 

For technical assistance with claiming CME credit, please email [email protected].
Refund/Cancellation Policy
The deadline for cancellations with refund is Monday, July 31, 2023. Cancellations must be received in writing and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization.

Please note that your SNO or ASCO membership must be current if you have chosen to register as a SNO or ASCO member. SNO reserves the right to confirm that you have registered in the correct category.

Payment must be received in full before access to the meeting can be granted.

Email all cancellation and transfer requests to Program Registrar Caroline Noor, [email protected] .

Questions? For all registration questions or for additional information, please contact Caroline Noor, Registrar, 830-321-0615 or [email protected]
Disclosure of Relevant Financial Relationships
The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. 

Click here for the disclosure list of all individuals in control of content for the program.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
SNO CME Contact Information
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Ritterhouse, RN at [email protected]

Click here to return to the 2023 SNO/ASCO Cancer Conference homepage.